Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
cephalosporin |
| gptkbp:approvalYear |
1994
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J01DE01
|
| gptkbp:brand |
gptkb:Maxipime
|
| gptkbp:CASNumber |
88040-23-7
|
| gptkbp:chemicalFormula |
C19H24N6O5S2
|
| gptkbp:contraindication |
hypersensitivity to cephalosporins
|
| gptkbp:discoveredBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:eliminationHalfLife |
2 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:generation |
fourth-generation cephalosporin
|
| https://www.w3.org/2000/01/rdf-schema#label |
cefepime
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits cell wall synthesis
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:proteinBinding |
16-19%
|
| gptkbp:routeOfAdministration |
intramuscular
intravenous |
| gptkbp:sideEffect |
seizures
allergic reactions gastrointestinal upset |
| gptkbp:spectrum_of_activity |
broad-spectrum
|
| gptkbp:usedFor |
bacterial infections
|
| gptkbp:bfsParent |
gptkb:cephalosporins
|
| gptkbp:bfsLayer |
6
|